Status:
COMPLETED
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Non-Small Cell
Neoplasm Metastasis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor. Each of these drugs have been given separately to patients in pri...
Eligibility Criteria
Inclusion
- Histologically documented advanced cancer, Eastern Cooperative Oncology Group (ECOG) 0-1;
- Platelets \> 100,000, ANC \> 1500;
- Ccr \> 60 or serum creat. \<1.5
- Non-small cell cancer cohort:
- Eastern Cooperative Oncology Group (ECOG) 0-2, prior platin, \< 4 prior chemotherapy regimen
- HgA1C \<5.7%
Exclusion
- Active Central Nervous System (CNS) metastases;
- prior IGF1-R targeted therapy
- Any history of unstable angina, myocardial infarction or symptomatic congestive heart failure.
Key Trial Info
Start Date :
December 15 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 29 2013
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT00728390
Start Date
December 15 2008
End Date
January 29 2013
Last Update
April 22 2024
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Amherst, New York, United States, 14221
2
Pfizer Investigational Site
Buffalo, New York, United States, 14263
3
Pfizer Investigational Site
San Antonio, Texas, United States, 78229
4
Pfizer Investigational Site
Villejuif, France, 94805